Cambridge Healthtech Institute’s 7th Annual
Small Molecules for Cancer Targets
Discovering Orally-BioAvailable, Targeted-Oncology Therapeutics
September 23-24, 2025
Join fellow discovery researchers at CHI’s Small Molecules for Cancer Targets conference to stay abreast of the new era of small-molecule based cancer drug discovery. Progress is mounting thanks to innovations in medicinal chemistry that allow targeting of specific cancer-associated molecules. Success is exemplified by two KRAS-based drugs recently having obtained regulatory approval and a few molecular degrader-based therapies in late-stage clinical trials. This new generation of targeted small-molecule anti-cancer candidates offer the potential of less toxicity than traditional chemotherapy because they are designed to destroy or inhibit cancer-specific targets only. Small molecule-based targeted oncology therapies also have advantages over biologics in that they offer the patient convenience of oral bioavailability and the potential to be deployed against wider range of targets because of their cell permeability.
Who should attend: Industry and Academic Scientists in departments such as: Discovery Oncology, Immuno-Oncology, Medicinal Chemistry, Oncology Therapeutics, Discovery Biology, Drug Discovery, Oncology Discovery, Immunology Discovery, Discovery Pharmacology
Coverage will include, but is not limited to:
- Small-molecule drug development progress against notorious oncology targets (p53, WRN, WNT, Ras)
- Targeted covalent inhibitors against cancer targets
- Updates on targeted protein destruction (TPD)-based oncology candidates
- Activator approaches for loss-of-function oncology targets
- Beyond biologics: small molecules as 2nd generation therapies against traditional IO biologic targets (e.g.; T cell checkpoint
inhibitors)
- GPCR-targeted small molecules for penetrating the tumor microenvironment (TME)
- Targeting integrins and cancer-associated macrophage (CAMs) targets with small molecules
- Cyclic peptide drug conjugate (PDC) strategies for improving small molecule cell selectivity and reducing cellular efflux
The deadline for priority consideration is March 7, 2025.
All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.
Opportunities for Participation: